Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 10/20 | 0.43 |
| ▸ | CNR1 | P21554 | 10/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2493222 | 0.95 | MAPT (0.47) | PDE3BPDE3AP2RY12TSHRCNR2 | |
| SCHEMBL3417582 | 0.84 | MAPT (0.38) | TSHRCNR2CNR1MAPTLTA4H | |
| SCHEMBL13008060 | 0.82 | MAPT (0.47) | PDE3BPDE3AP2RY12TSHRPDE2A | |
| SCHEMBL25455345 | 0.82 | CNR2 (0.46) | CNR2CNR1HDAC8 | |
| SCHEMBL12212283 | 0.81 | TSHR (0.48) | PDE3BPDE3AP2RY12TSHRMAPT | |
| SCHEMBL16092470 | 0.80 | ACHE (0.40) | CNR2CNR1 | |
| SCHEMBL7413008 | 0.80 | SMN1; SMN2 (0.49) | PDE3BPDE3AP2RY12TSHRMAPT | |
| SCHEMBL24132762 | 0.80 | MAPT (0.49) | PDE3BPDE3AP2RY12TSHRCNR2 | |
| SCHEMBL25456638 | 0.80 | CNR2 (0.52) | TSHRCNR2CNR1MAPT | |
| SCHEMBL13224054 | 0.80 | HDAC8 (0.42) | PDE3BPDE3AP2RY12TSHRCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238301-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2021-08-05 | — | — | US | disclosed |
| US-10947315-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190276552-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2019-09-12 | — | — | US | disclosed |
| US-10208127-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| EP-3100745-B1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20180079823-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079823-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2018-03-22 | — | — | US | disclosed |
| US-20170183419-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170183419-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-06-29 | — | — | US | disclosed |
| US-9550787-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-8802667-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130302357-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2013-11-14 | — | — | US | disclosed |
| US-20130302357-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2013-11-14 | — | — | US | disclosed |
| US-20130266596-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2013-10-10 | — | — | US | disclosed |
| US-20130266596-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2013-10-10 | — | — | US | disclosed |
| US-8426402-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426402-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC. (US) | 2010-08-12 | — | — | US | disclosed |
| WO-2010091150-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266596-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | PDE3B 2043/4885PDE3A 2948/4885P2RY12 1571/4885 |
| US-20210238301-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | PDE3B 2043/4885PDE3A 2948/4885P2RY12 1571/4885 |
| US-10208127-B2 | Benzodiazepine derivatives | GABBR1, GABRB1, GABRA1 | PDE3B 1756/4885PDE3A 2675/4885P2RY12 1588/4885 |
| US-20190276552-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | PDE3B 2043/4885PDE3A 2948/4885P2RY12 1571/4885 |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | PDE3B 2043/4885PDE3A 2948/4885P2RY12 1571/4885 |
| US-20170183419-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | PDE3B 2043/4885PDE3A 2948/4885P2RY12 1571/4885 |
| US-20130302357-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | PDE3B 2043/4885PDE3A 2948/4885P2RY12 1571/4885 |
| US-10947315-B2 | Benzodiazepine derivatives | GABBR1, GABRB1, GABRA1 | PDE3B 1756/4885PDE3A 2675/4885P2RY12 1588/4885 |
| US-20180079823-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | PDE3B 2043/4885PDE3A 2948/4885P2RY12 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.